SecBot SecBot
SECBOTREPLAY Home › Report › CCCC

CCCC · Jay L

C4 Therapeutics, Inc. · 144 filed Aug 14, 2026 at 18:56 ET

At the news

NEUTRALIMPACT 3/10

144 filed Aug 14, 2026 at 18:56 ET

Jay L. Geldmacher, a former REZI CEO and reporting owner of C4 Therapeutics, filed a Form 144 notice of intent to sell approximately 82,563 shares of common stock with an estimated aggregate market value of ~$1.9 million. The shares were acquired through restricted stock and performance share grants between 2024 and 2025. This is a relatively small sale relative to C4's $502M market cap, but the insider's role and the timing (no specific catalyst noted) warrant monitoring for potential follow-through sales or insider sentiment shifts.

  • Jay L. Geldmacher filed Form 144 to sell up to 82,563 shares of C4 Therapeutics common stock.
  • Estimated aggregate market value of the proposed sale is approximately $1,899,926.
  • Shares were acquired via restricted stock and performance share grants dated 02/09/2025, 02/14/2025, 02/15/2025, 02/18/2024, and 02/14/2024.
  • The filing date is August 14, 2026, with the proposed sale date also listed as August 14, 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access